Post Event Registration of Meet with... National Cancer Institute

Actions Panel

Post Event Registration of Meet with... National Cancer Institute

By JLABS @ TMC

Date and time

May 25, 2015 · 1pm - May 27, 2015 · 7pm CDT

Location

Texas Medical Center

John P. McGovern Campus 2450 Holcombe Blvd, Suite X Houston, TX 77021

Refund Policy

Contact the organizer to request a refund.

Description

JLABS TEXAS EVENT Program Overview:
NCI: SBIR Opportunities for Early-Stage and Venture-Backed Companies

Program Director Dr. Xing-Jian Lou will present and discuss the SBIR and STTR programs that fund and support small biomedical technology companies.

During this session, she will provide an update on funding opportunities available to small businesses as well as tips on strengthening your application. The SBIR program helps fill the gap in the availability of early stage funding created when investors and strategic partners move towards clinical-stage investments. SBIR funds serve as a key bridge between initial angel funding and more significant angel capital, venture capital, or strategic partnerships.

Additionally, the presentation will provide valuable information on NCI's other initiatives including the NCI SBIR Bridge Award, the NCI SBIR Investor Forum, and I-Corps(tm) at NIH. Get all of your questions answered during the Q&A session following the presentation and apply to meet one-on-one with Dr. Lou.

Agenda:
10:00 AM | Registration & Networking session
10:30 AM | Presentation & Q&A
11:50 AM | Lunch
12:30-5:00 PM | One-on-one Meetings*

*Companies must apply for a one-on-one meeting ahead of time and be approved. The application period ends on April 19th.

National Cancer Institute Participating Representative:
Dr. Xing-Jian Lou | Program Director, Small Business Innovation Research Development Center, National Cancer Institute read bio»

About the National Cancer Institute:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Fees:
Presentation & Lunch
$25 | General Public
$35 | General Public - At the door
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until May 18th (or full).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must apply for a one-on-one meeting ahead of time. The one-on-one application period ends on April 19th. Your application will be reviewed and you will be notified of acceptance by email. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Location:
Texas Medical Center
John P. McGovern Campus
2450 Holcombe Blvd, Suite X
Houston, TX 77021

Parking Information:
Please park in the self parking areas of the McGovern Campus. Grab a Token at the gate and bring it to the event space. We encourage carpooling and using the TMC shuttles.
TMC Map

National Cancer Institute Participating Representative's Biography:
Xing-Jian Lou Dr. Xing-Jian Lou | Program Director, Small Business Innovation Research Development Center, National Cancer Institute
Dr. Xing-Jian Lou is a Program Director in the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute (NCI). In this role, she actively engages in identifying areas of interest for NCI to develop Contract Topics and Funding Opportunity Announcements. She also conducts outreach events to help recruit more focused, commercially-minded SBIR applicants, and coaches small businesses to develop stronger applications and obtain government funding for innovative research and development projects with high commercial potential. Dr. Lou manages funded projects, mentoring and guiding companies throughout the award period, and facilitating their interaction with potential third-party investors and strategic partners. Dr. Lou has over 15 years experience in research and product development in the area of biomarker-, assay-, technology- and knowledgebase- development for diagnosis and drug development. Prior to joining NCI she held a variety of scientific and management positions in pharmaceutical and biotech companies, including Johnson & Johnson, LumiCyte, Applied Biosystems (now part of Thermo Fisher Scientific corporation) and diaDexus. Dr. Lou received her PhD degree in Molecular & Cellular Pharmacology from the Miller Medical School of the University of Miami and completed her postdoctoral training at Stanford University.
Connect with Xing: Connect on LinkedIn

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Thomas McNerney & Partners, NCATS, Poliwogg, and OrbiMed.

Organized by

Sales Ended